# Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation

> **NCT02723786** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 7 (actual)

## Conditions studied

- Kidney Transplantation (Status Post)

## Interventions

- **BIOLOGICAL:** GSK1070806
- **DRUG:** 1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids

## Key facts

- **NCT ID:** NCT02723786
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-08-27
- **Primary completion:** 2017-03-31
- **Final completion:** 2018-03-06
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Lack of efficacy
- **Last updated:** 2019-06-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02723786

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02723786, "Efficacy, Safety, Tolerability and Pharmacokinetic (PK) Study of GSK1070806 for the Prevention of Delayed Graft Function (DGF) in Adult Subjects After Renal Transplantation". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02723786. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*